hBMMSC
Phase 1Biologic
hBMMSC is one of 45 biologic programs targeting Autism Spectrum Disorder. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
55 competitors in Autism Spectrum Disorder
#DrugCompanyPhaseTrials
1Buspar
Bristol-Myers SquibbApproved
Namenda
AbbVieApproved
Marinol
Jazz PharmaceuticalsApproved
Aricept
EisaiApproved
Epidiolex
Jazz PharmaceuticalsApproved
Lioresal
NovartisApproved
Abilify
OtsukaApproved
Neurontin
VViatris Specialty LLC
Approved
Strattera
MMap77
Approved
Bendopa
MMerz North America, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Autism Spectrum Disorder1 trial
A Study of Mesenchymal Stem Cell in the Treatment of Autism Spectrum Disorder
Not yet recruiting·JJiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.·Phase 1·NCT07177677·42 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for hBMMSC. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details